Dr Reddy’s Labs Q3 Outcomes: Pharma firm Dr Reddy’s Laboratories on Thursday, January 23 introduced a 2% year-on-year enhance in consolidated revenue after tax (PAT) to ₹1,413.3 crore for the quarter ended December 2024 (Q3). The PAT in Q3 of final yr stood at ₹1,378.9 crore.
The income from operations for the mentioned quarter got here in at ₹8,358.6 crore, recording a 16% YoY leap versus ₹7,214.8 crore posted within the December 2023 quarter.
The expansion was largely pushed by revenues from the not too long ago acquired Nicotine Alternative Remedy(NRT) portfolio, revenues from India and Rising Markets, the corporate mentioned.
The worldwide generics phase income noticed a 17% YoY enhance in Q3 whereas the pharmaceutical companies and lively substances (API) phase witnessed a 5% progress in income.
The earnings earlier than curiosity, tax, depreciation and amortization in Q3 stood at ₹2,298.2 crore as towards ₹2,110.7 crore in the identical quarter final yr and ₹2,280.3 crore within the previous quarter of FY25.
In the meantime, the gross margin for the quarter underneath assessment was at 58.7%, according to 58.5% and decrease than 59.6% in Q2 FY25.
The corporate spent ₹6.7 billion on analysis and growth in Q3 FY25, which was 8% of the revenues. R&D investments are associated to our ongoing growth efforts throughout advanced generics, peptides, biosimilars, in addition to our novel oncology property.
Commenting on the outcomes, Co-Chairman & MD, G V Prasad mentioned, “We delivered double-digit progress aided by our newly acquired NRT enterprise, new launches and improved operational efficiencies. We stay dedicated to addressing affected person wants by advancing healthcare by entry, affordability and innovation.”
Efficiency for 9M FY25
The corporate’s topline efficiency for the nine-months ended December was robust, with income rising 15% YoY to ₹24047.5 crore. Nonetheless, revenue witnessed a 5% YoY decline to ₹4060 crore.
The EBITDA for the quarter got here in at ₹6738.4 crore, increased than ₹6429.3 crore posted in the identical quarter of the monetary yr 2023-24.
Dr Reddy’s Labs share value ended at ₹1289.35, down 0.54% on the BSE.
Disclaimer: The views and suggestions above are these of particular person analysts or broking firms, not Mint. We advise traders to test with licensed specialists earlier than making any funding choices.
